Metrics as of 10/16/2026, 07:55 AM (Berlin time), refresh in progress.
Diaceutics Stock
Diaceutics PLC
Company data
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Country
- United Kingdom
- CEO
- Ryan Keeling
- Employees
- 205
- Market cap
- £172 M
- IPO
- 21/03/2019
Diaceutics PLC, established in 2005 and headquartered in Belfast, UK, is a company dedicated to accelerating the commercialization of diagnostic solutions. It offers global pharmaceutical companies comprehensive data, advanced analytics, and implementation support. Central to its operations is the DXRX platform. This…
Diaceutics stock: price history
1D
+0.0%
1W
+0.2%
1M
+26.6%
6M
+22.7%
YTD
+58.2%
1Y
+23.5%
2Y
+51.7%
5Y
+81.6%
10Y
–
Next earnings date
Next earnings date
No date known
Volatility around earnings
~24% stronger price swings than usual
Ask the agents about Diaceutics
Diaceutics stock metrics
P/E
-632.81
P/B
4.42
EV/EBITDA
30
RETURN ON EQUITY
-7.1%
NET MARGIN
-15.9%
DEBT/EQUITY
0.05
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
57.2%
FLOAT SHARES
48,485,534
AVG. DAILY VOLUME (30D)
326,974
Comparable stocks
Frequently asked questions about Diaceutics stock
What does Diaceutics do?
Diaceutics PLC is a company in the Healthcare sector, Medical - Healthcare Information Services industry, headquartered in United Kingdom.
The CEO is Ryan Keeling, the company employs around 205 people.
The IPO was on 21/03/2019; the stock trades on LSE under the ticker DXRX.L.
When does Diaceutics report next?
Around past earnings, price swings were roughly 24% stronger than usual.
Does Diaceutics pay a dividend?
No, Diaceutics currently does not pay a dividend.
Which stocks are comparable to Diaceutics?
Comparable stocks include Optima Health, Hinge Health, HealthEquity, Heartflow, Omada Health, Teladoc Health, SOPHiA GENETICS and Evolent Health.
How can I get Diaceutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Diaceutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.